GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Transition Therapeutics Inc (NAS:TTHI) » Definitions » Unpaid Loss & Loss Reserve

Transition Therapeutics (Transition Therapeutics) Unpaid Loss & Loss Reserve


View and export this data going back to 2007. Start your Free Trial

What is Transition Therapeutics Unpaid Loss & Loss Reserve?

Unpaid Loss & Loss Reserve only applies to insurance companies.


Transition Therapeutics (Transition Therapeutics) Business Description

Traded in Other Exchanges
N/A
Address
Transition Therapeutics Inc was incorporated on July 6, 1998 as 'Transition Therapeutics and Diagnostics Inc.' The Corporation filed articles of amendment on October 12, 2000 and on October 19, 2000 to create a class of non-voting shares (the 'Class B Shares') and to amend certain attributes of its Common Shares. On November 2, 2000, the Corporation filed articles of amendment to delete its private company restrictions. On December 14, 2000, the Corporation filed articles of amendment to change its name to 'Transition Therapeutics Inc.' The Company's technologies are focused on the treatment of Alzheimer's disease and diabetes. The Corporation operates in one business segment; that is the research and development of therapeutic agents. Its technologies in development include ELND005 (AZD-103) for the treatment of Alzheimer's disease. On April 30, 2013, the Company announced the results of a five-week proof of concept clinical study of TT401 in type 2 diabetic and obese non-diabetic subjects. In the study, TT401, a once weekly administered peptide, demonstrated improvements in glycemic control and reductions in body weight.
Executives
Jack W Schuler 10 percent owner 100 N. FIELD DRIVE, SUITE 360, LAKE FOREST IL 60045
Family Foundation Schuler 10 percent owner 100 N. FIELD DRIVE, SUITE 360, LAKE FOREST IL 60045